www.aiq-services.com Open in urlscan Pro
192.124.249.178  Public Scan

Form analysis
0 forms found in the DOM

Text Content

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or
content, and analyze our traffic. By clicking "Accept All", you consent to our
use of cookies.

Customize Reject All Accept All
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions.
You will find detailed information about all cookies under each consent category
below.

The cookies that are categorized as "Necessary" are stored on your browser as
they are essential for enabling the basic functionalities of the site. ... Show
more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such
as providing secure log-in or adjusting your consent preferences. These cookies
do not store any personally identifiable data.

No cookies to display.

Functional

Functional cookies help perform certain functionalities like sharing the content
of the website on social media platforms, collecting feedback, and other
third-party features.

No cookies to display.

Analytics

Analytical cookies are used to understand how visitors interact with the
website. These cookies help provide information on metrics such as the number of
visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance

Performance cookies are used to understand and analyze the key performance
indexes of the website which helps in delivering a better user experience for
the visitors.

No cookies to display.

Advertisement

Advertisement cookies are used to provide visitors with customized
advertisements based on the pages you visited previously and to analyze the
effectiveness of the ad campaigns.

No cookies to display.

Reject All Save My Preferences Accept All
Skip to the content
AIQ Global Inc.
Menu
 * Home
 * Therapy Development
 * Tracer Development
 * Resources
 * Contact

AIQ Global Inc.
Menu
 * Home
 * Therapy Development
 * Tracer Development
 * Resources
 * Contact

Close Menu
 * Home
 * Therapy Development
 * Tracer Development
 * Resources
 * Contact

 * Facebook
 * Twitter
 * LinkedIn


HOME

mainback

mainback
Accelerating Therapy/Tracer
Development


Slide
Automatic Organ Segmentation

Retrospective 57 patient Phase I/II study comparing AIQ technology to
experienced reader for evaluating heterogeneous system amyloid build up in
multiple organs.

“This approach will significantly impact the ease of use and improve accuracy of
image interpretation that will ultimately benefit clinical management of
patients with amyloidosis.”

- Weisman et al., WMIC 2021


Click to View Full Poster
Slide
Assess Organ-Specific Toxicity: Immunotherapy Application

Retrospective study of 58 melanoma patients treated with ICI therapy evaluated
in a partnership with University of Wisconsin Carbone Cancer Center.

Accurate quantification of changes in the lung could significantly predict which
patients had pneumonitis prior to actual diagnosis with an AUC of 0.99.


Click to View Immunotherapy Application Note
Slide
Assess Organ-Specific Toxicity:
Theranostics Application

13 prostate cancer patients from a Phase I/II trial treated with 177 Lu-PSMA-617
and imaged pre- and post-treatment with 68Ga-PSMA11-PET.

Quantification of PSMA expression shows
1. Associations between PSMA PET SUV and response by both overall survival and
PSA response
2. Associations between degree of PSMA PET SUV in PSMA-expressing non-tumor
tissues and adverse events

Nauseef et al., American Society of American Society of Clinical Oncology
Genitourinary Cancers Symposium (ASCO-GU) 2022.


Click to View Full Poster




Our AI-driven software technologies provide comprehensive treatment response
assessments from imaging scans to improve patient outcomes.


Therapy Development

MORE EFFICIENT CLINICAL TRIALS

 * Treatment Response
 * Toxicity Assessment
 * Patient Selection


Learn More…



Tracer Development

DEEPER UNDERSTANDING OF RADIOPHARMACEUTICALS

 * Uptake Assessment
 * Concordance Analysis
 * Longitudinal Changes


Learn More…

Intended for research use only. Not intended for use in treatment of patients.

> “Partnering with AIQ Solutions on their new technology has been an enjoyable
> and productive collaboration. We share a mutual goal of improving patient care
> by leveraging innovative technology.”

Dr. Elisabeth I. Heath, M.D., FACP
Professor of Oncology and Medicine
Karmanos Cancer Institute

> “The AIQ software will greatly improve the interpretation of PET/CT and
> PET/MRI scans in patients who have had multiple exams. The analysis of these
> exams will be more thorough and comprehensive and should save the interpreting
> nuclear medicine physician or radiologist a lot of time.
> 
> The ability to determine which lesions have responded to therapy and which are
> resistant in patients with a large metastatic disease burden will allow great
> improvements in patient care and hopefully lead to improved survival in
> oncology patients. Software like this will surely be an important part of
> image interpretation in the future.”

Dr. Scott Perlman M.D., M.S.
University of Wisconsin School of Medicine and Public Health
Consultant to AIQ


 * Facebook
 * Twitter
 * LinkedIn

© 2024 AIQ Global Inc.

Privacy/Compliance Policy

Powered by WordPress

To the top ↑ Up ↑
modal-check


ALESSANDRA

Demo Description

Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA Pharma

Alessandra Cesano, MD, PhD is the Chief Medical Officer at ESSA Pharma since
July 2019. Previously she has been the Chief Medical Officer of NanoString Inc
from July 2015 until June 2019 where she focused in the development of
translational and diagnostic multi-plexed assays for the characterization and
measurement of mechanisms of immune response/resistance. Prior to joining
NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and
before then she served as Chief Medical Officer and Chief Operations Officer at
Nodality, Inc., where she built and led the R and D group, while providing the
overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano
held various management positions at Amgen, Biogen Idec and SmithKline Beecham
Pharmaceuticals, where she helped to advance various oncology drugs through late
stage development and FDA approvals. Early in her professional career Dr. Cesano
spent 12 years conducting research in tumor immunology, including nine years at
the Wistar Institute, an NCI Basic Cancer Center connected with the University
of Pennsylvania. She also holds membership in several professional and
scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the
latter she serves as co-chair in the SITC Industry Committee, Associate Editor
for the Biomarker section of JITC and is an active member of the SITC Biomarker
Working Group. Over her careers she has been an author on over 140 publications.
Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and
a PhD in Tumor Immunology from the University of Turin.

Dismiss ad Dismiss ad

This will close in 40 seconds



modal-check


SELVAGGI

Demo Description

Giovanni Selvaggi, PhD
Chief Medical Officer, Xcovery

Dr. Selvaggi held global positions of increasing responsibility in clinical
development at various global pharmaceutical companies prior to joining Xcovery
in March 2019. Dr. Selvaggi joined the pharmaceutical industry in 2010 as
Medical Director in the MAGE-A3 lung cancer vaccine program at GSK. He then
played an instrumental role in the successful development and approval of
ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis in 2013. Most
recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers
Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC
and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line
SCLC indication with NDA in 2018. Dr. Selvaggi received his medical degree at
the University of Torino School of Medicine, in Torino, Italy, in 1992 and
served as staff physician of thoracic oncology at the University Hospital in
Torino, participating in several clinical trials in lung cancer and mesothelioma
over a span of 16 years.

Dismiss ad Dismiss ad

This will close in 40 seconds



modal-check


ERIC

Demo Description

Eric Horler
President and Chief Executive Officer, AIQ Solutions

Eric Horler joined AIQ Solutions as its first President and CEO in September
2018. He has led AIQ through two rounds of equity financing, team construction,
product commercialization, and international expansion. Before joining the AIQ
team, Eric was President and CEO of Swallow Solutions LLC, a medical device
start-up with both therapeutic devices and functional beverages for dysphagia
patients. Before that, Eric was General Manager, Premium Anesthesia and
Respiratory Care at GE Healthcare. While at GEHC, Eric was responsible for a
$220 million global business and a large team spread over three continents. He
has also held a series of marketing and business development roles at Baxter
Healthcare, including Director of Renal Products and Services for the Latin
America region. Eric has a B.S. in Chemical Engineering from Rice University and
both an MBA and Master of Engineering Management degrees from the Kellogg School
of Business. He lives in Madison with his wife and two children.

Dismiss ad Dismiss ad

This will close in 40 seconds





 * Home
 * Therapy Development
 * Tracer Development
 * Resources
 * Contact


Information on this page is intended for research use only. Applications and/or
claims listed are not currently cleared for use in treatment of patients.